Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol. 2010 Sep;17 Suppl 2:S49-54.

Bone health in nonmetastatic prostate cancer: what's the big deal?

Author information

1
Urologic Oncology Division, Centre Hospitalier de l'Université de Montréal, Montreal, QC. jean-baptiste.lattouf@umontreal.ca

Abstract

Since 2000, the medical community has become increasingly aware of bone health in men with prostate cancer on androgen deprivation therapy (ADT)-mainly because of new therapies that have been shown to reduce bone loss and associated fractures in this patient population. The threat of bone complications has become even more concerning in the prostate-specific antigen era, because ADT is initiated earlier (with biochemical recurrence after local treatment) and maintained longer before the appearance of metastatic disease. The present review examines the relevance of bone health in nonmetastatic prostate cancer, with a discussion of the new treatment modalities available.

KEYWORDS:

Prostate cancer; androgen deprivation therapy; bisphosphonates; skeletal-related events

PMID:
20882134
PMCID:
PMC2935711
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multimed Inc. Icon for PubMed Central
    Loading ...
    Support Center